• Biogen exercises option on investigational ALS treatment BIIB067

    • December 8, 2018
    • Posted By : admin
    • 0 Comment
    •   78 views

    US biotech Biogen (Nasdaq: BIIB) has exercised its option to obtain from Ionis Pharmaceuticals (Nasdaq: IONS) a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations.

    ALS with SOD1 mutations is a subtype of familial ALS and accounts for around 2% of all ALS cases.

    The shares of both companies dipped by mid-morning trading today, with Biogen down 0.73% at $320.29, and Ionis falling 0.88% to $55.51.

    “Biogen and Ionis have a shared goal of bringing innovative therapies to those living with severe neurological diseases where there is significant unmet medical need,” said Dr Michael Ehlers, executive vice president, R&D at Biogen. “The progress made to date in the BIIB067 clinical program is a positive step forward. We are committed to our goal of bringing forward a therapy for patients with ALS with SOD1 mutations, who currently have limited or no treatment options,” he added.

  78 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!